Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Feng Zhang

David R. Liu

George Church

J. Keith Joung

Jennifer Doudna

Editas Medicine, Inc.

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

Scholar Rock is engaged in the discovery and development of innovative medicines, focusing on therapeutic approaches related to protein growth factors. It has a pipeline aimed at advancing the standard of care for neuromuscular diseases and other conditions.

Metric
Company Name	Editas Medicine, Inc.	BridgeBio Pharma	Instil Bio, Inc.	Scholar Rock
Symbol	EDIT		TIL
MSH ID	COM:EDITASMEDICINE	COM:BRIDGEBIOPHARMA	COM:INSTILBIO	COM:SCHOLARROCK
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage		Post-IPO Equity
Employee Count	265		49
Website	editasmedicine.com	bridgebiopharma.com	instilbio.com	scholarrock.com
LinkedIn
Founders

Metric
Market Cap	417.77M		65.10M
Enterprise Value
Monthly Web Traffic	38.30K	23.81K	12.72K
Web Traffic Growth	2.72	0.19	-0.76
Valuation
Raised Capital	125M	250M

Metric
Revenue	78.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	72.06M
EBITDA	-163.12M
Operating Income	-169.18M
Net Income	-153.22M
EPS	-2.02
Diluted EPS	-2.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.93
Operating Profit Margin	-2.10
EBITDA Margin	-2.09
Net Profit Margin	-1.92
Return on Equity	-0.42
Return on Assets	-0.30
Return on Capital Employed	-0.38

COM:EDITASMEDICINE

Editas Medicine

Last Close

2.37

22/11 21:00

Market Cap

417.77M

Beta: -

Volume Today

2.25M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.11
P/B Ratio	1.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.93
EV Multiple	-1.33

Metric
Days Sales Outstanding	35.92
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	47.59
Cash Conversion Cycle	-450.13
Asset Turnover	0.17

Metric
Operating Cash Flow	-132.18M
Free Cash Flow	-136.90M
Cash Flow to Debt	-3.62
Operating Cash Flow/Sales	-1.69
Free Cash Flow Yield	-0.20

Metric
Cash & Equivalents	123.65M
Accounts Receivable	-5.04M
Inventory
Goodwill
Debt to Capitalization	0.14
Debt to Assets	0.07
Current Ratio	7.62
Quick Ratio	5.27

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.74
R&D to Revenue	5.08
SG&A to Revenue	2.97